Having treatment protocols for the rich countries and alternative protocols for the poor ones still nurtures global health disparities
People think cancer care is unaffordable because of the high prices of cancer medicines. Some state that innovations in oncology mostly happen thanks to massive investments in the private sector.
A survey reveals that physicians outside the field of oncology are insufficiently updated on the latest advances in cancer care, thus increasing the risk of providing misleading information and inadequate support to patients.
Despite the encouraging findings of a new global survey demonstrating a high rate of uptake of the ESMO/ASCO Global Curriculum in Medical Oncology, resource limitations in lower-income regions as well as country-specific political circumstances may be hindering its implementation locally.
Discrepancies in anti-cancer drug approvals around the globe are even bigger in low- and middle-income countries, raising some questions about how they impact on patients’ access to quality cancer care.
The scope of the oncology care across resource-diverse settings has been long debated.
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community
Faced with an explosion in the complexity of genomic, imaging and clinical data, AI is rapidly becoming an indispensable tool for oncologists.
According to Prof. Urania Dafni, high quality real-world evidence can provide broader information and more generalisable conclusions to verify the clinical applicability of evidence from RCTs
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.